Aims-To evaluate diVerent hybridisation techniques to detect and type human papillomavirus (HPV) DNAs amplified by consensus primer polymerase chain reaction (PCR) in biopsy and cytological specimens. Methods-A hybrid capture-immunoassay in microtitre wells was performed to detect HPV sequences amplified by PCR and typed by specific oligoprobes. Consensus primers were used to amplify a sequence within the L1 open reading frame, and direct digoxigenin labelling of amplified products was performed during the amplification reaction. The amplified product was separately hybridised with six biotinylated type specific probes (HPV6, 11, 16, 18, 31, and 33); hybrids were then captured into streptavidin coated microtitre wells and detected by a spectrophotometer as an ELISA using antidigoxigenin Fab fragment labelled with peroxidase and a colorimetric substrate. The results were compared with the dot-blot immunoassay used to detect and type PCR amplified HPV DNA sequences. Consensus primers were used to generate the same unlabelled PCR product; digoxigenin labelled type specific probes for HPV6, 11, 16, 18, 31, and 33 were used and hybrids visualised by colorimetric immunoenzymatic reaction. Thirty nine biopsy specimens and 31 cytological samples were tested by the PCR-ELISA and by standard PCR followed by dot-blot hybridisation. Results-The PCR-ELISA proved to be more sensitive than standard PCR with dot-blot hybridisation typing. All samples positive for HPV-DNA in standard PCR with dot-blot hybridisation method were confirmed positive by the PCR-ELISA assay; however, seven samples were positive only by PCR-ELISA. Conclusions-The PCR-ELISA assay, which can be performed in one day, is easily standardised and therefore seems to be a practical, sensitive, and reliable diagnostic tool for the detection and typing of HPV genomes in biopsy and in cytological specimens in the routine diagnostic laboratory.
Human papillomavirus (HPV) infections are related to several cutaneous and mucosal dysplasias, including both benign and malignant lesions.
1- 8 The HPVs are commonly referred to as high, intermediate or low oncogenic risk, depending on the frequency with which they are associated with malignancy. The high risk types include HPV16, 18, 45, and 56; HPV31, 33, and 35 are intermediate risk types; and HPV6, 11, 42, 43, and 44 are low risk.
As HPVs cannot be propagated in cell cultures, and only small amounts of viral antigens are present in body fluids, 9 the diagnosis of HPV infection mainly relies on HPV nucleic acid detection. 10 The most common methods used to detect and type HPV DNAs are: Southern blot, 11 12 dot-blot, 13 in situ hybridisation (ISH), 14 15 and polymerase chain reaction (PCR).
Nucleic acid amplification techniques such as PCR 16 are valid tools for the diagnosis of HPV related diseases. 17 In fact PCR amplification allows rapid and specific detection of low abundance viruses and a single genome copy can be detected in clinical specimens. Many PCR protocols use either primers recognising specific HPV open reading frames (ORFs) 18 or common highly conserved sequences among diVerent HPV types. 19 20 Typing of HPV DNA generated by PCR with consensus primers can be performed by restriction fragment length polymorphism, 21 by direct DNA sequence analysis, 22 and by dot-blot hybridisation with type specific probes. 23 Several hybrid capture immunoassays have recently been developed for the detection and typing of PCR products. [24] [25] [26] [27] [28] [29] In this study a hybridisation capture assay in microplates was compared to dot-blot hybridisation for the detection and typing of PCR amplified HPV DNAs in 39 paraYn wax embedded biopsies and 31 cytological specimens.
Methods

CLINICAL SPECIMENS
Ten micrometer sections were cut from 39 paraYn wax embedded biopsy samples. Tissue specimens were selected according to clinical, histological, and/or histochemical findings: 3 were classified as warts, 7 as genital condylomas, 1 as Bushke-Lowenstein tumour, 5 as cervical intraepithelial neoplasias (CIN I and CIN II), 3 as epithelial lesions of the penis, 6 as squamous cell carcinomas, 3 as cutaneous Bowen's disease, 2 as bowenoid papulosis, 2 as verrucous carcinomas, 1 as laryngeal lesion, 1 as tongue condyloma, 3 as papular lesions in epidermodysplasia verruciformis, and 2 as gastric papillomas.
Thirty one cervical scrapes were selected according to clinical, colposcopic, cytological, and/or histochemical findings: 3 were classified as cervical condylomas, 18 as CIN I, 6 as CIN II, and 4 as CIN III.
All 70 clinical specimens and 4 reference clinical specimens negative for HPV DNAs were tested either by standard PCR 19 with dotblot hybridisation 23 or by the PCR-ELISA method.
SPECIFICITY AND SENSITIVITY CONTROLS
The cervical carcinoma cell line CaSki, which contains 500-600 HPV16 DNA copies per cell, and HeLa, which contains 20-50 HPV18 DNA copies per cell, were used as positive controls. To determine the sensitivity of standard PCR dot-blot hybridisation and the PCR-ELISA method, 10-fold dilutions up to 10 −6 of 10 3 HeLa or CaSki cell lysates were tested.
Four paraYn wax embedded biopsy specimens, analysed by ISH (Kreatech, the Netherlands) with subgenomic type specific probes and proved positive for HPV6, 11, 31, and 33 respectively, were used as positive controls. The biopsies were dewaxed and digested as described below. Then end point dilutions of the lysates were performed and tested by standard PCR with dot-blot hybridisation. The highest dilution, which proved positive by standard PCR with dot-blot hybridisation, was introduced as a reference positive control for the PCR-ELISA method.
Human fibroblast cell line MRC-5 was used as a negative control. Ten microliters of 10 3 MRC-5 cell lysate were processed. In addition, reference specimens from four paraYn wax embedded cutaneous biopsies unrelated to HPV induced lesions and negative for HPV DNAs were analysed. The values obtained for the MRC-5 negative control by PCR-ELISA were in the range of the values obtained for reference specimens negative for HPV DNAs (p < 0.01).
DNA PREPARATION
ParaYn wax embedded sections from biopsy specimens were dewaxed twice in xylene, dehydrated in absolute ethanol, and protease digested by incubation at 55°C for two hours in 200 µl of digestion buVer (50 mM KCl, 10 mM Tris-HCl pH 8.3, 0.05% Tween 20 and 400 µg/ml of proteinase K), followed by heat inactivation at 95°C for 10 minutes.
Cytological specimens from cervical scrapes were collected in phosphate buVered saline (PBS), centrifuged, and the pellets digested with buVer as described above.
Confluent monolayers from HeLa, CaSki, and MRC-5 cell lines were harvested by trypsinisation, washed with PBS, and spun down. The pellet was digested with buVer as described above.
PRIMERS AND PROBES
Consensus primer pair MY09 and MY11, 19 able to detect more than 25 diVerent HPV types within the L1 ORF, were used in PCR amplification.
Oligonucleotide probes MY12, MY13, MY14, WD74, WD128, and MY59 23 specific to the L1 PCR products of HPV6, 11, 16, 18, 31, and 33, respectively, were used in hybridisation reactions.
As amplification control, primers GH20 and PC04, 30 recognising human globin gene sequence, were used in each PCR reaction and amplified products were detected by PC03 probe.
All the hybridisation probes used in the PCR-ELISA method were 5' labelled with biotin, while all hybridisation probes used in standard PCR with dot-blot hybridisation were 5' labelled with digoxigenin.
STANDARD PCR AND DOT-BLOT HYBRIDISATION
Standard PCR was performed simultaneously for amplification of HPV sequences and human globin sequence. HPVs were amplified by consensus primers. 19 Amplification products were visualised through 2% agarose gel with ethidium bromide staining and were then analysed by dot-blot hybridisation 23 with digoxigenin labelled internal probes specifically for HPV types 6, 11, 16, 18, 31, and 33. Hybridised digoxigenin labelled probes were then visualised colorimetrically by immunoenzymatic reaction using antidigoxigenin Fab fragments labelled with alkaline phosphatase. 31 
PCR-ELISA METHOD
DNA amplification and labelling DNA amplification and labelling was performed in 50 µl PCR reaction volume containing 50 mM KCl, 10 mM Tris-HCl pH 8.2, 4 mM MgCl 2 , 0.1 mM dATP, 0.1 mM dGTP, 0.1 mM dCTP, 0.095 mM dTTP, 0.005 mM digoxigenin-11-dUTP (Boehringer Mannheim, Mannheim, Germany), 0.1 µM each primer MY09, MY11, GH20, and PC04, 2.5 Units Taq DNA polymerase, and 10 µl of each digested sample.
After an initial denaturation step at 95°C for five minutes, 40 cycles were performed of one minute at 95°C, one minute at 55°C, two minutes at 72°C, followed by a final extension step of five minutes at 72°C.
Hybridisation and detection reaction
Amplified products, labelled with digoxigenin during the amplification reaction, were separately hybridised with type specific biotinylated probes for HPV6, 11, 16, 18, 31, and 33, and with biotinylated probe for human globin gene sequence. A volume of 5 µl of amplified product was added to 5 µl of denaturing solution (100 mM NaOH, 0.1% and incubated at 25°C for 10 minutes. Then 190 µl of hybridisation solution (300 mM NaCl, 100 mM Tris-HCl pH 6.5, 10 mM EDTA, 0.1% Tween-20), containing 2 pmol/ ml of a type specific probe were added and hybridisation was performed at 55°C for 10 minutes. Each reaction volume was transferred to a streptavidin coated microtitre plate well (Boehringer Mannheim) and incubated at 25°C for 50 minutes. Plates were then washed five times with TBST (150 mM NaCl, 100 mM Tris-HCl pH 7.5, 0.1% Tween-20). A volume of 200 µl of antidigoxigenin POD conjugated solution (10 mU/ml in TBST) (Boehringer Mannheim) was added and incubated at 25°C for 30 minutes. After washing five times in TBST, 200 µl of ABTS substrate solution was added to each well, and developed for 30 minutes at room temperature. The colorimetric reaction was measured by spectrophotometry at the optical density (OD) of 405 nm.
As the values of the MRC-5 negative control were in the range of values obtained for reference negative specimens, the cut oV of the reaction was determined as twice the mean value of a negative MRC-5 control tested in triplicate. This corresponds to the OD value obtained from HeLa and CaSki cell lysates containing 20-50 copies of HPV18 DNA and 50-60 copies of HPV16 DNA, respectively. Test samples with values in the range of ±20% of the cut oV value were retested.
Results were expressed as net absorbence after the absorbence of the buVer blank was subtracted and index value was calculated as OD of the sample/cut oV; index value > 1 was considered positive.
Results
To determine the optimum amount of type specific probes to use in the hybridisation reaction, four diVerent concentrations (1, 2, 5, and 10 pmol/ml) of WD74 or MY14 probes specific for HPV18 and HPV16, respectively, were hybridised with PCR amplified products obtained from 10-fold dilutions of 10 3 HeLa ( fig 1A) or CaSki ( fig 1B) cell lysates, respectively.
The hybridisation signal reached the maximum value when a concentration of 2 pmol/ml of each probe was used at the diVerent concentrations of HeLa or CaSki cells tested. The signal remained constant even at higher probe concentrations. Therefore a probe concentration of 2 pmol/ml was used in all the experiments.
To determine the sensitivity of the reaction, a lysate from 10 3 HeLa or CaSki cells was diluted up to 10 −6 and amplified by PCR. Hybridisation and capture assay of amplified products proved positive up to 10 −4 for CaSki (about 50-60 genome copies) and up to 10 −3 for HeLa cells (about 20-50 genome copies) (fig 2) . When the same dilutions of HeLa and CaSki cell lysates were amplified by standard PCR and detected with digoxigenin labelled specific probes, the assay proved positive up to 10 −3 for CaSki cells and up to 10 −2 for HeLa cells. The specificity of the PCR-ELISA was assessed on MRC-5 cell lysate. No amplified products were detected when PCR treated MRC-5 cell lysate was hybridised with type specific probes for HPV6, 11, 16, 18, 31, and 33, and captured in a microtitre plate well. No cross reactions were observed when amplified products from HeLa were hybridised with MY12, MY13, MY14, WD128, MY59 specific for HPV6, 11, 16, 31, and 33, respectively, and amplified products from CaSki were hybridised with MY12, MY13, WD74, WD128, MY59 specific for HPV6, 11, 18, 31, and 33, respectively (data not shown).
To test the reproducibility of the PCR assay, dilutions from HeLa and CaSki cell lysates were amplified in three independent PCR assays and amplified products detected by the ELISA method in the same plate. The diVerence observed in OD values between replicate PCR samples was assessed at about 4%. To measure the reproducibility of the ELISA method, dilutions from HeLa and CaSki cell lysates were amplified in PCR and hybridised with specific probes. The hybrids were captured in three diVerent streptavidin coated wells and the diVerence observed in OD values between replicate samples was assessed at about 2%.
As , respectively. Thirty nine paraYn wax embedded tissue specimens and 31 cytological specimens were tested by the PCR-ELISA method. All the specimens had previously been analysed by standard PCR and typed by dot-blot hybridisation with specific probes. With the standard technique, 23 samples had proved negative for HPV6, 11, 16, 18, 31, and 33, and 16 had proved positive for HPV DNAs (table 1) . Of the cytological samples tested, 13 were negative and 18 positive (table 2) .
With the PCR-ELISA method 18 of the 39 biopsy specimens analysed proved negative for HPV DNAs, and 21 proved positive (table 1) . Eleven of the 31 cytological specimens analysed proved negative for HPV DNAs and 20 proved positive (table 2). All biopsy and cytological specimens were positive for human globin gene sequence. Reference positive controls proved positive in each experiment with both methods tested. Four reference negative biopsies proved negative both by standard PCR with dot-blot hybridisation and by the PCR-ELISA method. No cross contaminations from microtome cut were detected-paraYn slices treated as clinical specimens proved negative for HPV6, 11, 16, 18, 31, and 33 DNA, and there was no contamination during PCR amplification tested by the presence of MRC-5 negative controls and blank samples (PCR reagents without a DNA template) run in each assay.
To test the reproducibility of the results, three positive and two negative clinical specimens by the PCR-ELISA were retested in three independent assays and the results were confirmed.
All samples positive for HPV DNA by standard PCR with dot-blot hybridisation method were confirmed positive in the PCR-ELISA assay; however, seven samples were positive only by PCR-ELISA: 2 were identified as HPV6, 2 as HPV16, 1 as HPV18, 1 as HPV31, and 1 as HPV33.
Discussion
Several diagnostic techniques have been used for the diagnosis of HPV infections. Currently PCR assay oVers the greatest sensitivity and the use of consensus primers allows the amplification of a broad spectrum of HPV types. 19 20 32 Many technical strategies have been developed to type and quantify HPV DNA sequences amplified by consensus primers. 27 We evaluated a semiquantitative method to detect and type HPV amplified sequences, this method, able to give an objective evaluation of the results, was compared with dot-blot hybridisation.
33-39
In the PCR-ELISA, the well conserved L1 region of the HPV genome was amplified by consensus primers and directly labelled with digoxigenin during amplification reaction. The direct incorporation of a labelled nucleotide during amplification reaction increases the sensitivity of the assay with respect to extension labelling primers, giving a more eYcient labelling. 24 In fact, one digoxigenin-dUTP is incorporated approximately every 20 dTTPs into an amplified region of 450 base pairs.
The specificity and typing of amplified products was assured by biotinylated oligoprobes specific for HPV16, 18, 31, 33, 6, and 11, considered at high, intermediate, and low risk for their oncogenic potential. This method, however, can be adapted to the detection of all HPV genotypes and represents a valid tool to study the pathogenicity of the diVerent genotypes.
The PCR-ELISA method can be adapted to screen HPV DNA positive clinical samples using MY18 and MY57 generic probes, 23 but in our experience the assay proved less sensitive with degenerated probes (data not shown). Furthermore, a second hybridisation reaction to identify type specific HPV DNAs is necessary. However, if the diagnosis of the laboratory can be limited to detect HPV DNAs and discriminate the oncogenic potential of HPVs, the use of two cocktails of oligonucleotide probes can be used to recognise high and low risk HPVs. 27 39 This method is less time consuming and technically demanding but it allows only a limited reduction of costs as the cost is mainly attributable to the probes.
Digoxigenin labelled PCR products, hybridised with specific biotinylated probes, were captured into streptavidin coated microtitre wells by a biotin-streptavidin binding and detected by an immunoenzymatic reaction. 29 The colorimetric reaction was automatically detected by spectrophotometry and semiquantitative determination of HPV type specific DNA was achieved by comparison with positive reference samples. Of the 39 biopsy specimens and the 31 cytological scrapes tested, 18 and 11, respectively proved negative by both the PCR-ELISA and standard method. These results could indicate that the clinical diagnosis does not always correlate with the laboratory investigation. Otherwise HPV genotypes other than those investigated could be present.
When the 70 clinical specimens were tested both by the PCR-ELISA and the standard PCR with dot-blot hybridisation, seven samples were positive by the PCR-ELISA only. The discrepancy of the results could be interpreted as a higher sensitivity for the PCR-ELISA than standard PCR with dot-blot hybridisation, probably because of the higher eYciency of the labelling method used.
With the PCR-ELISA, evaluation of results is objective and semiquantitative data can be obtained, while dot-blot hybridisation requires a subjective interpretation and, at low viral concentration, the interpretation of the results could be doubtful.
The possibility of obtaining semiquantitative data by the PCR-ELISA is particularly useful as the viral load seems to predict the clinical course of the infection and is implicated in maternal-infant transmission. 35 40 This assay can be performed in one day, is easily standardised and therefore seems to be a practical, sensitive, and reliable diagnostic tool for the detection and typing of HPV genomes in biopsy and cytological specimens in the routine diagnostic laboratory.
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